JPRN-UMIN000011039已完成未知
The effect of Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist,after cardiac surgery - The effect of Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist,after cardiac surgery
Juntendo University Faculty of Medicine0 个研究点目标入组 100 人开始时间: 2013年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •history of dialysis severe renal failure (eGFR<15mL/min/1.73m2) emergent surgery maximum blood pressure is less than 100mmHg any other patient who are in contraindicated of Torvaptan
研究者
相似试验
已完成
不适用
ong-term Effect of Tolvaptan Administration for Outcome and Neurohormonal Factors in Patients with Heart Failureheart failureJPRN-UMIN000013807ihon University Surugadai Hospital100
尚未招募
不适用
sefulness of Tolvaptan tablet over Furosemide injection in reducing swelling in Nephrotic syndromeCTRI/2022/10/046590Department of Pediatrics
已完成
不适用
ongitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease PatientsAutosomal Dominant Polycystic Kidney DiseaseJPRN-UMIN000021267Autosomal Dominant Polycystic Kidney Disease Research Section, Kyorin University, School of Medicine119
已完成
不适用
Comparison of Tolvaptan treatment and conventional treatment in elderly acute heart failure.Acute decompensated heart failureJPRN-UMIN000028039Iiyama redcross hospital60
已完成
4 期
Effects of low dose oral tolvaptan add on benefit in patients hospitalized for acute decompensated heart failure: A randomized controlled trialAcute decompensated heart failure is a common condition which increases morbidity and cardiovascular mortality. Most patients often suffer from dyspnea. The main treatments are to treat precipitating causes of AHF and to use diuretics for getting rid of water and salt from the body. Tolvaptan may improve these symptoms.TCTR20210316012/A40